|
|
Blood, 15 September 2005, Vol. 106, No. 6, pp. 2018-2025.
Prepublished online as a Blood First Edition Paper on May 24, 2005; DOI 10.1182/blood-2005-02-0642.
Previous Article | Next Article 
Submitted February 15, 2005
Accepted May 15, 2005
Reduced frequencies and suppressive function of CD4+ CD25high regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine
Marc Beyer, Matthias Kochanek, Kamruz Darabi, Alexey Popov, Markus Jensen, Elmar Endl, Percy A Knolle, Roman K Thomas, Michael von Bergwelt-Baildon, Svenja Debey, Michael Hallek, and Joachim L Schultze*
Molecular Tumor Biology and Tumor Immunology, University of Cologne, Cologne, Germany; Clinic I for Internal Medicine, University of Cologne, Cologne, Germany
Institute for Molecular Medicine and Experimental Immunology, University of Bonn, Bonn, Germany
Clinic I for Internal Medicine, University of Cologne, Cologne, Germany
* Corresponding author; email: joachim.schultze{at}uk-koeln.de.
Globally suppressed T cell function has been described in many cancer patients to be a major hurdle for the development of clinically efficient cancer immunotherapy. Inhibition of anti-tumor immune responses has been mainly linked to inhibitory factors present in cancer patients. More recently, increased frequencies of CD4+ CD25high regulatory T cells (Treg cells) have been described as an additional mechanism reducing immunity. Assessing 73 B cell chronic lymphocytic leukemia (CLL) patients and 42 healthy controls we demonstrate significantly increased frequencies of CTLA4+ FOXP3+ GITR+ CD62L+ TGF 1+ IL-10+ Treg cells in CLL patients, with highest frequencies in untreated or progressing patients presenting with extended disease. Most surprisingly, in the majority of CLL patients treated with fludarabine containing therapy regimens the inhibitory function of Treg cells was decreased or even abrogated. In addition, frequencies of Treg cells were significantly decreased after therapy with fludarabine. In light of similar findings for cyclophosphamide the combination of fludarabine and cyclophosphamide might be further exploited in strategies reducing immune suppression prior to cancer immunotherapy.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. A. Burger, P. Ghia, A. Rosenwald, and F. Caligaris-Cappio
The microenvironment in mature B-cell malignancies: a target for new treatment strategies
Blood,
October 15, 2009;
114(16):
3367 - 3375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Zhang, T. F. Gajewski, and J. Kline
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Blood,
August 20, 2009;
114(8):
1545 - 1552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. B. Olkhanud, D. Baatar, M. Bodogai, F. Hakim, R. Gress, R. L. Anderson, J. Deng, M. Xu, S. Briest, and A. Biragyn
Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells
Cancer Res.,
July 15, 2009;
69(14):
5996 - 6004.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Gertner-Dardenne, C. Bonnafous, C. Bezombes, A.-H. Capietto, V. Scaglione, S. Ingoure, D. Cendron, E. Gross, J.-F. Lepage, A. Quillet-Mary, et al.
Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies
Blood,
May 14, 2009;
113(20):
4875 - 4884.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. TOKUNO, S. HAZAMA, S. YOSHINO, S. YOSHIDA, and M. OKA
Increased Prevalence of Regulatory T-Cells in the Peripheral Blood of Patients with Gastrointestinal Cancer
Anticancer Res,
May 1, 2009;
29(5):
1527 - 1532.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Hirschowitz and J. R. Yannelli
Immunotherapy for Lung Cancer
Proceedings of the ATS,
April 15, 2009;
6(2):
224 - 232.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Gorgun, A. G. Ramsay, T. A. W. Holderried, D. Zahrieh, R. Le Dieu, F. Liu, J. Quackenbush, C. M. Croce, and J. G. Gribben
E{micro}-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction
PNAS,
April 14, 2009;
106(15):
6250 - 6255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X.-J. Qin, H.-Z. Shi, J.-M. Deng, Q.-L. Liang, J. Jiang, and Z.-J. Ye
CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion
Clin. Cancer Res.,
April 1, 2009;
15(7):
2231 - 2237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Curti, S. Trabanelli, V. Salvestrini, M. Baccarani, and R. M. Lemoli
The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology
Blood,
March 12, 2009;
113(11):
2394 - 2401.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kottke, J. Thompson, R. M. Diaz, J. Pulido, C. Willmon, M. Coffey, P. Selby, A. Melcher, K. Harrington, and R. G. Vile
Improved Systemic Delivery of Oncolytic Reovirus to Established Tumors Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2
Clin. Cancer Res.,
January 15, 2009;
15(2):
561 - 569.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. de Jong, A. Koster, A. Hagenbeek, J. Raemaekers, D. Veldhuizen, S. Heisterkamp, J. P. de Boer, and M. van Glabbeke
Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols
Haematologica,
January 1, 2009;
94(1):
70 - 77.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Jak, R. Mous, E. B. Remmerswaal, R. Spijker, A. Jaspers, A. Yague, E. Eldering, R. A.W. van Lier, and M. H. J. van Oers
Enhanced Formation and Survival of Regulatory T Cells in CLL.
Blood (ASH Annual Meeting Abstracts),
November 16, 2008;
112(11):
1065 - 1065.
[Abstract]
|
 |
|

|
 |

|
 |
 
K. Koyama, H. Kagamu, S. Miura, T. Hiura, T. Miyabayashi, R. Itoh, H. Kuriyama, H. Tanaka, J. Tanaka, H. Yoshizawa, et al.
Reciprocal CD4+ T-Cell Balance of Effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage
Clin. Cancer Res.,
November 1, 2008;
14(21):
6770 - 6779.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Caligaris-Cappio and P. Ghia
Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease?
J. Clin. Oncol.,
September 20, 2008;
26(27):
4497 - 4503.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mittal, N. A. Marshall, L. Duncan, D. J. Culligan, R. N. Barker, and M. A. Vickers
Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma
Blood,
June 1, 2008;
111(11):
5359 - 5370.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Yokokawa, V. Cereda, C. Remondo, J. L. Gulley, P. M. Arlen, J. Schlom, and K. Y. Tsang
Enhanced Functionality of CD4+CD25highFoxP3+ Regulatory T Cells in the Peripheral Blood of Patients with Prostate Cancer
Clin. Cancer Res.,
February 15, 2008;
14(4):
1032 - 1040.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Nishikawa, T. Tsuji, E. Jager, G. Briones, G. Ritter, L. J. Old, J. E. Galan, H. Shiku, and S. Gnjatic
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector
Blood,
February 1, 2008;
111(3):
1404 - 1412.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Haas, L. Schopp, B. Storch-Hagenlocher, B. Fritzsching, C. Jacobi, L. Milkova, B. Fritz, A. Schwarz, E. Suri-Payer, M. Hensel, et al.
Specific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitis
Blood,
January 15, 2008;
111(2):
761 - 766.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Qiao, H. Wang, T. Kottke, C. White, K. Twigger, R. M. Diaz, J. Thompson, P. Selby, J. de Bono, A. Melcher, et al.
Cyclophosphamide Facilitates Antitumor Efficacy against Subcutaneous Tumors following Intravenous Delivery of Reovirus
Clin. Cancer Res.,
January 1, 2008;
14(1):
259 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Bell, P. A. Svingen, M. K. Rahman, Y. Xiong, and W. A. Faubion Jr.
Forkhead Box P3 Regulates TLR10 Expression in Human T Regulatory Cells
J. Immunol.,
August 1, 2007;
179(3):
1893 - 1900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Beyer and J. L. Schultze
CD4+CD25highFOXP3+ Regulatory T Cells in Peripheral Blood Are Primarily of Effector Memory Phenotype
J. Clin. Oncol.,
June 20, 2007;
25(18):
2628 - 2630.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kretz-Rommel, F. Qin, N. Dakappagari, E. P. Ravey, J. McWhirter, D. Oltean, S. Frederickson, T. Maruyama, M. A. Wild, M.-J. Nolan, et al.
CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy
J. Immunol.,
May 1, 2007;
178(9):
5595 - 5605.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Perez, M. V. Karamouzis, D. V. Skarlos, A. Ardavanis, N. N. Sotiriadou, E. G. Iliopoulou, M. L. Salagianni, G. Orphanos, C. N. Baxevanis, G. Rigatos, et al.
CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu (HER)-Positive and HER-Negative Advanced-Stage Breast Cancer Patients
Clin. Cancer Res.,
May 1, 2007;
13(9):
2714 - 2721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Baatar, P. Olkhanud, K. Sumitomo, D. Taub, R. Gress, and A. Biragyn
Human Peripheral Blood T Regulatory Cells (Tregs), Functionally Primed CCR4+ Tregs and Unprimed CCR4- Tregs, Regulate Effector T Cells Using FasL
J. Immunol.,
April 15, 2007;
178(8):
4891 - 4900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. P. Hilchey, A. De, L. M. Rimsza, R. B. Bankert, and S. H. Bernstein
Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25- and CD4+CD25- T Cells
J. Immunol.,
April 1, 2007;
178(7):
4051 - 4061.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. v. Rhee
Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System
Clin. Cancer Res.,
March 1, 2007;
13(5):
1353 - 1355.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hansson, A. O. Abdalla, A. Moshfegh, A. Choudhury, H. Rabbani, B. Nilsson, A. Osterborg, and H. Mellstedt
Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients
Clin. Cancer Res.,
March 1, 2007;
13(5):
1503 - 1510.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sharma, A. L. Dominguez, and J. Lustgarten
High Accumulation of T Regulatory Cells Prevents the Activation of Immune Responses in Aged Animals
J. Immunol.,
December 15, 2006;
177(12):
8348 - 8355.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. J. Bates, S. B. Fox, C. Han, R. D. Leek, J. F. Garcia, A. L. Harris, and A. H. Banham
Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse
J. Clin. Oncol.,
December 1, 2006;
24(34):
5373 - 5380.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Brode, T. Raine, P. Zaccone, and A. Cooke
Cyclophosphamide-Induced Type-1 Diabetes in the NOD Mouse Is Associated with a Reduction of CD4+CD25+Foxp3+ Regulatory T Cells
J. Immunol.,
November 15, 2006;
177(10):
6603 - 6612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Tinhofer, G. Rubenzer, C. Holler, E. Hofstaetter, M. Stoecher, A. Egle, M. Steurer, and R. Greil
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia
Blood,
November 1, 2006;
108(9):
2950 - 2956.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Carreras, A. Lopez-Guillermo, B. C. Fox, L. Colomo, A. Martinez, G. Roncador, E. Montserrat, E. Campo, and A. H. Banham
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
Blood,
November 1, 2006;
108(9):
2957 - 2964.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-Z. Yang, A. J. Novak, S. C. Ziesmer, T. E. Witzig, and S. M. Ansell
Attenuation of CD8+ T-Cell Function by CD4+CD25+ Regulatory T Cells in B-Cell Non-Hodgkin's Lymphoma.
Cancer Res.,
October 15, 2006;
66(20):
10145 - 10152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L Sommer, B. K Wachel, and J. A Smith
Evaluation of vaccine dosing in patients with solid tumors receiving myelosuppressive chemotherapy
Journal of Oncology Pharmacy Practice,
September 1, 2006;
12(3):
143 - 154.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ishida, T. Ishii, A. Inagaki, H. Yano, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda
Specific Recruitment of CC Chemokine Receptor 4-Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege
Cancer Res.,
June 1, 2006;
66(11):
5716 - 5722.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Beyer, M. Kochanek, T. Giese, E. Endl, M. R. Weihrauch, P. A. Knolle, S. Classen, and J. L. Schultze
In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma
Blood,
May 15, 2006;
107(10):
3940 - 3949.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. McWhirter, A. Kretz-Rommel, A. Saven, T. Maruyama, K. N. Potter, C. I. Mockridge, E. P. Ravey, F. Qin, and K. S. Bowdish
Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation
PNAS,
January 24, 2006;
103(4):
1041 - 1046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. C. Di Paolo, S. Tuve, S. Ni, K. E. Hellstrom, I. Hellstrom, and A. Lieber
Effect of Adenovirus-Mediated Heat Shock Protein Expression and Oncolysis in Combination with Low-Dose Cyclophosphamide Treatment on Antitumor Immune Responses
Cancer Res.,
January 15, 2006;
66(2):
960 - 969.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. H. Prabhala, P. Neri, J. E. Bae, P. Tassone, M. A. Shammas, C. K. Allam, J. F. Daley, D. Chauhan, E. Blanchard, H. S. Thatte, et al.
Dysfunctional T regulatory cells in multiple myeloma
Blood,
January 1, 2006;
107(1):
301 - 304.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|